Drozitumab  (Synonyms: 曲齐妥单抗; PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody)

Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma^[1][2][3].

Human IgG1 lambda

Human IgG1 lambda1, Isotype Control

Drozitumab selectively eliminates cancer stem cells (CSCs), resulting in tumor growth inhibition and even regression of pancreatic tumors^[3].
Drozitumab induces apoptosis in mesenchymal TNBC cell lines but not in cell lines from other breast cancer subtypes^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

912628-39-8

液体

Colorless to light yellow

曲齐妥单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda

• 
  Loaded TRAIL R2/TNFRSF10B Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78220) on AHC2 biosensor, can bind Drozitumab with an affinity constant of 1.051E-08 M as determined in BLI assay.

• [1]. Dine JL, et al. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016 Jan;155(2):235-51.  [Content Brief]

  [2]. Kang Z, et al. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res. 2011 May 15;17(10):3181-92.  [Content Brief]

  [3]. Eng JW, et al. Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. J Immunother Cancer. 2016 Jun 21;4:33.  [Content Brief]